Back to Ingredient Dictionary
Common Name(s): Eyeseryl,ac-beta-ala-his-ser-his
CAS Number: 820959-17-9
DESCRIPTION
What It Does: Reduces periorbital puffiness and edema by limiting hyaluronan accumulation and improving vascular integrity.
Why It's Used: Targeted eye peptide for comprehensive under-eye treatment addressing puffiness, dark circles, and loss of firmness through multiple complementary mechanisms.
How It Works: Inhibits hyaluronan-protein cross-linking that causes excessive water retention (edema) under eyes. also reduces vascular permeability and improves lymphatic drainage. anti-glycation activity reduces skin stiffness.
Typically Found In: Eye creams,under-eye serums,anti-puffiness products
TECHNICAL DETAILS
Primary Category: Active ingredient โ eyeseryl eye peptide
Secondary Functions: Anti-edema,dark circle reduction,eye firmness
Application Areas:
Facial Skincare
Body Care
Hair Care
Beard Care
Color Cosmetics (Makeup)
Dietary/Oral Supplements
Typical Concentration Range: 50โ500 ppm
SOURCING & ETHICS
Vegan Status: Yes โ synthetically produced
Halal Status: Yes
Source Notes: Spps synthesis. commercially available as eyeseryl (lipotec).
SKIN COMPATIBILITY
Irritancy Rating: 1/5 โ very low
Comedogenicity Rating: 0/5 โ non-comedogenic
Sensitivity Concerns: Non-irritating; suitable for all skin types.
Safe for Sensitive Skin: Yes
SAFETY & COMPATIBILITY
Safety Profile: Exceptional safety profile. ewg score: 1.
Works Well With: Hyaluronic acid,ceramides,retinol,vitamin c,niacinamide
Avoid Combining With: Avoid mixing with high-concentration ahas at same ph (may hydrolyze peptide bonds)
SCIENTIFIC NOTE
Under-eye puffiness is driven by hyaluronan accumulation (water binding) and impaired lymphatic drainage. eyeseryl's inhibition of ha-protein crosslinking reduces the osmotic water-trapping capacity of the extracellular matrix, providing a mechanistically unique anti-puffiness approach.
Last Verified: Cosing database,lipotec eyeseryl technical data,clinical study journal of cosmetic dermatology
Primary Sources: 2026-03-12